By Anita Dushyanth, PhD
MYOS RENS Technology, Inc. ( MYOS) announced on April 10, 2018 that it has expanded its product line with the addition of Yolked™. This product, also based on Fortetropin®, is expected to be marketed specifically to competitive athletes. Yolked™ received the Certified for Sport® certification from NSF International.
NSF International is an independent organization that provides third-party certification of manufacturing systems and processes as well as for food, water and other products. NSF certification is widely accepted across the globe that the product and processes have met the requisite quality and safety standards. NSF’s “Certified for Sport” designation, for dietary and sports supplements, verifies that:
‣ The ingredients are free of banned substances (270+) as listed by major athletic organizations
‣ The contents of the product match with what is printed on the label
‣ There are no harmful levels of contaminants in the products
‣ The product is manufactured at a GMP facility inspected twice annually for quality and safety
NSF International’s Certified for Sport® program helps athletes make informed decisions when choosing sports supplements. MYOS hopes that Yolked™ will have a major presence in training facilities of collegiate and professional sports teams. Having all of the company’s products as NSF or BSCG certified prevents consumers and athletes from inadvertent doping.
In late 2017, MYOS entered into a strategic partnership with IMG College, to market its products to collegiate athletic programs. MYOS will commence featuring its products in certain Division 1 schools to students and alumni this year. We think this could highlight the company’s support of these athletic programs as they intend to establish trust and reputation for their products amongst fans and alumni.
READ THE FULL RESEARCH REPORT HERE.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
By Anita Dushyanth, PhD